BIOCEPT, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-06: Form 8-K; Period of report 2017-12-05; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2017-11-09: Form 8-K; Period of report 2017-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2017-09-29: Form 8-K; Period of report 2017-09-27; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
- 2017-09-08: Form 8-K; Period of report 2017-09-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-06 | 8-K | 2017-12-05 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On December 6, 2017, the Company issued a press release announcing the offering described in Item 1.01 above, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | bioc-8k_20171205.htm |
| 2017-11-09 | 8-K | 2017-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2017, we issued a press release announcing our financial results for the three and nine-months ended September 30, 2017. | bioc-8k_20171109.htm |
| 2017-09-29 | 8-K | 2017-09-27 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | bioc-8k_20170927.htm | |
| 2017-09-08 | 8-K | 2017-09-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 6, 2017, Edward Neff notified Biocept, Inc. (the “Company”) that, in order to be able to focus more time on other business efforts, he is resigning as a member of the Company’s Board of Directors (the “Board”) and as a member of all committees of the Board, effective as of September 8, 2017. | d453520d8k.htm |
| 2017-08-10 | 8-K | 2017-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2017, we issued a press release announcing our financial results for the three and six-months ended June 30, 2017. | bioc-8k_20170810.htm |
| 2017-08-10 | 8-K | 2017-08-09 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 The information set forth in Item 1.01 of this Current Report on Form 8-K that relates to the unregistered sale of equity securities is incorporated by reference into this Item 3.02. | bioc-8k_20170809.htm |
| 2017-05-11 | 8-K | 2017-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2017, we issued a press release announcing our financial results for the three months ended March 31, 2017. | bioc-8k_20170511.htm |
| 2017-05-05 | 8-K | 2017-05-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 As discussed below in Item 5.07, on May 2, 2017, Biocept, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders approved the Company’s Amended and Restated 2013 Equity Incentive Plan, as amended (the “2013 Plan”), to, among other things, increase the number of shares of the Company’s common stock available for issuance under the 2013 Plan from 1,022,955 to 3,522,955. 5.07 On May 2, 2017, the Company held the Annual Meeting. | bioc-8k_20170502.htm |
| 2017-03-30 | 8-K | 2017-03-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 Please see the disclosure regarding the Warrants and the Warrant Shares set forth under Item 1.01, which is incorporated by reference into this Item 3.02. 8.01 On March 28, 2017, the Company issued a press release announcing the offering described in Item 1.01 above, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | bioc-8k_20170328.htm |
| 2017-03-23 | 8-K | 2017-03-21 | 5.08 Shareholder Director Nominations | 5.08 On March 21, 2017, the Board of Directors (the “Board”) of Biocept, Inc. (the “Company”) set May 2, 2017 as the date for the Company’s 2017 Annual Meeting of Stockholders (the “Annual Meeting”). | bioc-8k_20170321.htm |
| 2017-03-07 | 8-K | 2017-03-07 | 2.02 Results of Operations and Financial Condition | 2.02 On March 7, 2017, we issued a press release announcing our financial results for the three months and year ended December 31, 2016. | bioc-8k_20170307.htm |
| 2017-02-09 | 8-K | 2017-02-09 | 8.01 Other Events | 8.01 On February 9, 2017, Biocept, Inc. (the “Company”) issued a press release highlighting the Company’s key accomplishments in 2016 and outlining the Company’s anticipated value drivers for 2017. | bioc-8k_20170209.htm |
| 2017-01-25 | 8-K | 2017-01-24 | 8.01 Other Events | 8.01 On November 28, 2016, Biocept, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company had failed to comply with the $1.00 per share minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). | bioc-8k_20170124.htm |